AstraZeneca Partners with Quell Therapeutics in $2 Billion+ Deal to Advance Engineered Treg Cell Therapies for Autoimmune Diseases

On June 9, AstraZeneca announced an agreement with Quell Therapeutics to develop multiple engineered regulatory T cell (Treg) therapies, which have the potential to cure type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

According to the terms of the agreement, Quell's proprietary Treg cell engineering modular toolbox will be utilized to develop autologous multi-module Treg cell candidate therapies for autoimmune diseases.

Quell to Receive $85 Million Upfront Payment from AstraZeneca, with Potential for Over $2 Billion in Additional Development and Commercialization Milestones.

Quell Therapeutics, a UK-based biotechnology company focused on engineered Treg cell therapy, completed a $156 million Series B financing round in 2021.

Quell Therapeutics CEO Iain McGill stated: "We are delighted to have AstraZeneca as our first partner. We are proud and thrilled to combine our leading science with AstraZeneca's extensive experience to accelerate the application of our Treg cell therapy platform in major autoimmune diseases."

References：

https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-agreement-with-quell-therapeutics.html

PharmaCube Pro

New Targets, New Technologies, New Therapies

Media cooperation: 15895423126

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message to the WeChat Official Account's backend or send a message, and specify the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.